advertisement
11.14 Investigational drugs; pharmacological experiments (29)
Showing records 1 to 25
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Ha A
Acta Ophthalmologica 2022; 100: e470-e477
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Naik M
Clinical Ophthalmology 2021; 15: 2683-2692
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Olander KW
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Sakata R
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim YK
Acta Ophthalmologica 2022; 100: e470-e477
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Fujishiro T
Japanese Journal of Ophthalmology 2021; 65: 591-597
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Sato MA
Journal of Glaucoma 2021; 30: 473-480
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Kapur M
Clinical Ophthalmology 2021; 15: 2683-2692
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Saito H
Japanese Journal of Ophthalmology 2021; 65: 591-597
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Gupta V
Clinical Ophthalmology 2021; 15: 2683-2692
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Jeoung JW
Acta Ophthalmologica 2022; 100: e470-e477
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Abrams MA
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Nakamura N
Japanese Journal of Ophthalmology 2021; 65: 591-597
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Jerkins GW
Journal of Glaucoma 2021; 30: 473-480
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Sethi H
Clinical Ophthalmology 2021; 15: 2683-2692
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Satyal S
Acta Ophthalmologica 2022; 100: e470-e477
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Honjo M
Japanese Journal of Ophthalmology 2021; 65: 591-597
94982 Ripasudil Endgame: Role of Rho-Kinase Inhibitor as a Last-Ditch-Stand Towards Maximally Tolerated Medical Therapy to a Patient of Advanced Glaucoma
Srivastava K
Clinical Ophthalmology 2021; 15: 2683-2692
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Lu F
Journal of Glaucoma 2021; 30: 473-480
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Kim J; Kim S
Acta Ophthalmologica 2022; 100: e470-e477
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Dinh P
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Shirato S
Japanese Journal of Ophthalmology 2021; 65: 591-597
94605 A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
Odani-Kawabata N
Journal of Glaucoma 2021; 30: 473-480
94608 Recovery of deepening of the upper eyelid sulcus after switching from prostaglandin FP receptor agonists to EP2 receptor agonist: a 3-month prospective analysis
Miyamoto E
Japanese Journal of Ophthalmology 2021; 65: 591-597
94934 Sovesudil (locally acting rho kinase inhibitor) for the treatment of normal-tension glaucoma: the randomized phase II study
Park KH
Acta Ophthalmologica 2022; 100: e470-e477
